Antibiotic Regimen for Pneumonia in Smokers

Treatment Algorithm Based on Severity and Setting

The British Thoracic Society recommends combined oral therapy with amoxicillin and a macrolide (erythromycin or clarithromycin) for hospitalized patients with non-severe community-acquired pneumonia 1, 2, 3
For smokers with non-severe community-acquired pneumonia in the outpatient setting, amoxicillin is the preferred agent, but at a higher dose than previously recommended 3
A macrolide (erythromycin or clarithromycin) is an alternative choice for those with penicillin hypersensitivity 3
For smokers specifically, careful consideration should be given to the possibility of resistant organisms 1, 2

Most patients can be adequately treated with oral antibiotics 2
Combined oral therapy with amoxicillin and a macrolide (erythromycin or clarithromycin) is preferred for patients requiring hospital admission 2, 4
When oral treatment is contraindicated, recommended parenteral choices include intravenous ampicillin or benzylpenicillin, together with erythromycin or clarithromycin 2

Patients with severe pneumonia should be treated immediately with parenteral antibiotics 4
An intravenous combination of a broad-spectrum β-lactamase stable antibiotic (co-amoxiclav, cefuroxime, cefotaxime, or ceftriaxone) together with a macrolide (clarithromycin or erythromycin) is preferred 4, 5

Smokers are at higher risk of underlying malignancy and should have a follow-up chest radiograph arranged at around 6 weeks, especially those over 50 years 1, 2

For patients with non-severe microbiologically undefined pneumonia, 7-10 days of treatment is typically sufficient 4
For patients with severe microbiologically undefined pneumonia, 10 days of treatment is proposed 4
Treatment should be extended to 14-21 days where legionella, staphylococcal, or Gram-negative enteric bacilli pneumonia are suspected or confirmed 4

Underestimating the severity of pneumonia in smokers, who may have compromised respiratory function at baseline 2
Failing to arrange appropriate follow-up imaging for smokers, who are at higher risk for underlying malignancy 1, 2
Using fluoroquinolones as first-line therapy when other options are available, which may contribute to antimicrobial resistance 2, 4